Overview

Selinexor Xpovio represents a genuinely different resistance strategy: instead of blocking a receptor or kinase, it traps tumor-suppressor proteins inside the nucleus. For myeloma programs that have exhausted standard classes, this mechanism offers a route after multi-drug resistance. This article focuses on that resistance angle and its practical implications.

How It Works

Selinexor is a selective inhibitor of nuclear export, binding the XPO1 (CRM1) transporter that normally shuttles proteins out of the nucleus. By blocking XPO1, it keeps tumor-suppressor and growth-regulatory proteins trapped where they belong, restoring apoptotic signaling in cancer cells. Because it acts on a trafficking step rather than a single mutation, it can remain active after resistance to proteasome inhibitors and immunomodulatory drugs has developed.

Indications

Indications include relapsed or refractory multiple myeloma after at least one prior therapy, in combination with dexamethasone, and certain diffuse large B-cell lymphoma. It is positioned for disease that has progressed through multiple classes, where alternative options are limited. Use requires attention to cytopenias and gastrointestinal tolerance through dose management.

Dosage & Administration

The myeloma regimen is 80 mg taken orally on days 1, 3, and 5 of each week, supplied as four 20 mg tablets, together with dexamethasone. The thrice-weekly pattern continues until progression or unacceptable toxicity. Dose reductions step down by 20 mg increments per event, so inventory should support the 20 mg strength as the building block.

Dexamethasone is taken on the same days to blunt nausea, and the day-3 and day-5 doses should not be shifted without prescriber review.

Storage & Sourcing

Store tablets at 20 to 25 °C, dry and light-protected, in original packaging. For resistant disease settings, demand is concentrated in heavily pretreated cohorts, so forecast against active treatment lines rather than broad populations. Confirm GMP status and batch documentation, and keep packaging intact because the intermittent schedule increases handling frequency.

Because the 20 mg tablet is the building block for both full and reduced doses, keep that strength as the primary stocked unit.

FAQ

Q: Why is Selinexor useful after proteasome and IMiD failure? A: It targets nuclear export rather than those pathways, so it can work when cells have become resistant to bortezomib or lenalidomide classes.

Q: How does the day 1, 3, 5 schedule affect sourcing? A: The thrice-weekly pattern means steady weekly consumption of the 20 mg tablet; plan replenishments around treatment continuity, not monthly cycles.

Q: What tolerability issues shape ordering? A: Nausea and low counts are managed with dose steps and supportive care; size orders to the reduced strength so adjustments do not strand full-strength stock.